| 货号 | 包装规格 | 操作 |
|---|---|---|
| SML4152-10MG | 10 mg | |
| SML4152-50MG | 50 mg |
≥98%（HPLC）
Ipragliflozin is a potent and highly selective sodium-glucose cotransporter-2 (SGLT2) inhibitor, demonstrating excellent oral bioavailability with an IC50 of 1,876 nM for SGLT1and 7.38 nM for hSGLT2. Ipragliflozin features dose-dependent pharmacokinetics, effectively induces glucosuria, and has been shown to decrease blood glucose levels, reduce blood pressure, lower body weight, and diminish both hypoglycaemic risk and abdominal symptoms in diabetic patients. Additionally, Ipragliflozin increases insulin levels in the pancreas and prevents the loss of insulin-positive cells in islets of db/db mice. ASP-1941 also maintains a favourable safety profile as monotherapy and is compatible with other hypoglycaemic agents, such as sulphonyl urea, metformin, pioglitazone, and dipeptidyl peptidase-4 (DPP4) inhibitors. Ipragliflozin has been considered as an anti-obesity and anti-diabetic agent. PMID 25685284
| 英文名称 | Ipragliflozin |
| CAS 号 | 761423-87-4 |
| 经验分子式 | C21H21FO5S |
| 分子量 | 404.45 |
| NACRES | NA.21 |
| SMILES字符串 | O[C@H]1[C@@H](O[C@H](CO)[C@@H](O)[C@@H]1O)C2=CC(CC3=CC4=CC=CC=C4S3)=C(F)C=C2 |
| 含量测定 | ≥98%（HPLC） |
| 形态 | 粉末 |
| 颜色 | 白色至米色 |
| 溶解性 | DMSO: 2 mg/mL，清澈 |
| 储存温度 | -10 到 -25°C |
| 质量等级 | 100 |
| 包装规格（货号 SML4152-10MG） | 10 mg |
| 包装规格（货号 SML4152-50MG） | 50 mg |
